CJC-1295 vs sermorelin vs tesamorelin vs ipamorelin

Last updated 2026-07-24

What are CJC-1295, sermorelin, tesamorelin, and ipamorelin, in plain terms?

All four are peptides that push on the growth hormone (GH) axis, but they don't do it the same way, and that difference matters more than most marketing pages let on. Sermorelin is a synthetic fragment of growth hormone-releasing hormone (GHRH), specifically the first 29 amino acids of the 44-amino acid native hormone. It was studied extensively enough in children with growth hormone deficiency that a full review of its diagnostic and treatment use was published in the peer-reviewed literature ^[1]. It has a short half-life, so it mimics the body's natural pulsatile GH release fairly closely. CJC-1295 is also a GHRH analog, but it's chemically modified (often with or without a compound called DAC, drug affinity complex) to extend its half-life far beyond native GHRH or sermorelin. The DAC version binds serum albumin and can stay active for days rather than minutes. This is a research chemical, not an FDA-approved drug. Tesamorelin is the outlier here: it's the only one of the four with current FDA approval, specifically for reducing excess abdominal fat in HIV patients with lipodystrophy. You can confirm any drug's approval status yourself using the FDA's own Drugs@FDA database ^[2]. Ipamorelin isn't a GHRH analog at all. It's a ghrelin mimetic, part of a class called growth hormone secretagogues (GHS) that work through a different receptor (GHSR-1a) than GHRH peptides do. Research on GH secretagogues in hypogonadal men found they raised IGF-1 levels, which is the marker doctors use as a proxy for GH axis activity ^[3]. Ipamorelin has no FDA approval for any indication.

How do these four peptides actually compare, side by side?

Here's the comparison most people are actually looking for, condensed into one table. Read the approval column carefully. It's the single biggest differentiator among these four, and it's the thing most sales pages gloss over.

Is sermorelin FDA-approved, and what happened to Geref?

Sermorelin was sold in the US under the brand name Geref, and it did go through FDA approval for diagnosing and treating growth hormone deficiency, primarily in children. That's a real regulatory history that most peptides being sold today simply don't have. Geref was discontinued. This is worth being precise about, because it gets misrepresented constantly: discontinuation is a business decision, usually about market size, manufacturing cost, or a company shifting priorities, not a finding that the drug was unsafe. It is not the same as an FDA safety withdrawal, and nothing in the sermorelin literature suggests the product was pulled for a safety signal. What this means practically: sermorelin itself, as a molecule, has a documented clinical history in a way CJC-1295 and ipamorelin do not. A 2006 review of adult-onset GH insufficiency treatment discussed sermorelin's mechanism and clinical rationale directly ^[4]. That doesn't mean today's sermorelin products are FDA-approved drugs, because they're not sold as Geref anymore. Most sermorelin available now comes through compounding pharmacies, which operate under a different regulatory framework than an approved drug product.

How are these peptides regulated today if none are sold as approved drugs (except tesamorelin)?

This is where things get legally specific, and it's the part people researching these peptides most often get wrong. Tesamorelin is the only one of the four available as an FDA-approved drug product, and only for its approved indication (HIV-associated lipodystrophy). Anything else it's used for is off-label, which is legal for a prescriber to do but isn't the same as FDA approval for that use. Sermorelin, since Geref's discontinuation, is generally available through compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a ^[5]. Compounded drugs use bulk substances, and the FDA maintains specific lists of what compounders can legally use. The 503A bulks list is at 21 CFR 216.23 ^[6], and the 503B list (for outsourcing facilities that compound at larger scale) is at 21 CFR 216.24 ^[7]. The FDA also publishes its own plain-language guidance on bulk substances used under 503A ^[8] and a running list of nominated substances under review ^[9]. CJC-1295 and ipamorelin sit in murkier territory. Neither is on the FDA's approved bulk substances list for compounding, which is a meaningful regulatory gap compared to sermorelin. Products sold as "research use only" are a separate category entirely, not intended for human use, and buying them for personal injection carries risks that have nothing to do with the peptide's biology and everything to do with what's actually in the vial. A 2016 investigation into falsified biopharmaceutical injectables in Europe documented real contamination and mislabeling problems in this exact gray market ^[10].

How is sermorelin different from HGH (growth hormone) itself?

This is probably the question that brought you here, so let's answer it straight, including where sermorelin comes up short. HGH (somatropin) is the hormone itself, injected directly. It bypasses the pituitary gland entirely and raises GH and IGF-1 levels directly and predictably. Sermorelin, CJC-1295, and tesamorelin don't contain any growth hormone at all. They're GHRH analogs that signal the pituitary to make and release its own GH. Ipamorelin works similarly but through the ghrelin receptor instead. The practical difference: GHRH analogs depend on a person having a functioning pituitary with adequate somatotroph reserve. If someone's pituitary can't respond, these peptides won't do much. HGH itself doesn't have that dependency, because it's the finished hormone. This is exactly why sermorelin was originally studied and approved as a diagnostic tool: giving it and measuring the GH response tells you whether the pituitary can respond at all, which is clinically useful information in growth hormone deficiency workups ^[1]. On magnitude, direct HGH injection produces a larger, more predictable, and more sustained rise in IGF-1 than GHRH analogs generally do, because it isn't gated by pituitary responsiveness or feedback inhibition. That's the honest tradeoff: sermorelin works with the body's own regulatory feedback loops (which some clinicians consider a safety feature, since it's harder to grossly overshoot GH levels), but that same feedback loop caps how much effect you'll get. If a patient has significant pituitary damage or panhypopituitarism, sermorelin is very likely the weaker choice clinically, and direct HGH replacement is usually necessary. For a deeper look at what results typically look like on sermorelin specifically, see sermorelin peptide before and after.

What is CJC-1295 actually used for, and how does it differ from sermorelin?

CJC-1295 does the same basic job as sermorelin (stimulating the GHRH receptor) but with a much longer duration of action. The DAC-modified version is engineered specifically to stick around, sometimes for days, by binding to albumin in the blood. That sounds like an advantage on paper: fewer injections. But the pulsatile pattern of natural GH release matters physiologically, and flattening that pulsatility with a long-acting agent is a real pharmacologic tradeoff, not a free upgrade. Sermorelin's short half-life is actually a deliberate feature in the approved GHRH-analog design tradition, it lets GH rise and fall in something closer to a normal daily rhythm. CJC-1295 has no FDA approval and hasn't gone through the kind of long-term human trials that sermorelin (via Geref) or tesamorelin have. Research use is where most of the current literature sits. Recent peptide-safety reviews covering musculoskeletal and performance contexts specifically flag CJC-1295 and similar unapproved GH secretagogues as needing more rigorous human safety data before broader clinical use ^[11][12].

What is tesamorelin approved for, and can it be used off-label?

Tesamorelin is FDA-approved specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That's a narrow, specific indication, confirmed in the FDA's own drug database ^[2]. Off-label use (for general fat loss, anti-aging framing, or athletic purposes) does happen in clinical practice, and prescribers are legally allowed to prescribe approved drugs off-label. But off-label doesn't mean equally studied. The evidence base tesamorelin was approved on is specific to lipodystrophy in HIV patients, and extrapolating those results to a healthy 45-year-old wanting to lose belly fat is not something the approval covers. Some clinics discuss combining tesamorelin with sermorelin, on the theory that tesamorelin's stronger, more stabilized GHRH signal pairs with sermorelin's shorter pulsatile pattern. If you're looking into that specifically, can stack tesamorelin and sermorelin covers what's actually known about combining the two, which is less than most stacking discussions imply.

What is ipamorelin, and how is it different from the three GHRH peptides?

Ipamorelin is a ghrelin receptor agonist, meaning it works on a completely different receptor (GHSR-1a) than sermorelin, CJC-1295, and tesamorelin, which all act on the GHRH receptor. Both pathways converge on the same downstream effect (more GH release from the pituitary), but through separate mechanisms. Because the mechanisms differ, some research has looked at combining a GHRH analog with a ghrelin-mimetic like ipamorelin, on the idea that hitting both pathways at once produces more GH release than either alone. That's a real pharmacologic concept in the growth hormone secretagogue literature, and a 2020 review on GH secretagogues in hypogonadal men body composition management discusses this combined-mechanism approach directly ^[13]. It is not the same as evidence that ipamorelin alone, or any specific stack, produces particular body composition or anti-aging outcomes in healthy adults, and ipamorelin has no FDA approval for any use. Ipamorelin is often marketed as "cleaner" than older ghrelin mimetics because it's more selective for GH release without strongly triggering cortisol or prolactin release the way some older secretagogues do. That selectivity claim comes from receptor-binding pharmacology, not from large controlled human outcome trials.

What does sermorelin dosing typically look like compared to these others?

Sermorelin is typically dosed as a nightly subcutaneous injection, timed before bed to work with the body's natural largest GH pulse, which occurs during early sleep. Doses in the clinical literature and typical prescribing practice are small, in the microgram range, reflecting its role as a signaling peptide rather than a replacement hormone. CJC-1295 (especially the DAC form) is dosed less frequently precisely because of its extended half-life, sometimes just once or twice a week in the way it's used in research and off-label practice. Tesamorelin, per its approved labeling, is dosed as a daily subcutaneous injection. Ipamorelin, when used, tends to follow a similar nightly or multi-daily pattern to sermorelin because of its short half-life. None of this dosing guidance applies if you're getting these compounds from an unregulated seller with no clinical oversight. A prescriber who orders bloodwork (IGF-1 levels, at minimum) before and during treatment is doing something meaningfully different from a website that ships a vial with a generic protocol card.

What do independent safety reviews actually say about these peptides?

Recent reviews are more cautious than the marketing language around these peptides. A 2026 review of therapeutic peptides in orthopaedics discusses GH-axis peptides among a broader category of applications, but frames the evidence base as still developing, with real gaps in long-term human data ^[11]. A companion 2026 review specifically on peptide therapies for musculoskeletal injury and athletic performance evaluated both approved and unapproved peptides and found safety and efficacy data uneven across the category, with unapproved compounds like CJC-1295 and ipamorelin having far thinner human evidence than approved drugs ^[12]. A separate 2026 review focused specifically on performance-enhancing peptides affecting the GH-IGF1 axis describes a real gap between what's clinically documented and what's happening in patient self-administration outside medical supervision ^[14]. That's a direct way of saying: people are using these compounds faster than the science is confirming what they do long-term. One unusual finding worth flagging honestly: a 2021 paper explored sermorelin as a potentially effective drug in patients with recurrent glioma ^[15], and a case report described anterior cervical osteophyte-related dysphagia in a long-term growth hormone user ^[16]. Neither of these findings should be over-generalized, they're specific, isolated reports, not signals that sermorelin causes brain tumors or neck problems. But they're a reminder that GH-axis manipulation isn't inert, and long-term users deserve monitoring, more than a prescription and a goodbye.

Why is detecting these peptides in doping tests such an active research area?

If you've noticed a surprising number of analytical chemistry papers on GHRH detection, that's not a coincidence. These peptides are banned in competitive sports under anti-doping rules, and detecting synthetic GHRH analogs distinct from a person's natural GHRH is technically hard, which has kept lab scientists busy for over a decade. Multiple methods have been developed: cationic exchange solid-phase extraction combined with triple quadrupole mass spectrometry for urine testing ^[17], antibody-free ultrafiltration assays capable of detecting GHRH at low picogram-per-milliliter concentrations ^[18], immunoaffinity purification methods for plasma ^[19], and magnetic bead-based purification techniques for high-resolution mass spec workflows ^[20]. A 2021 review specifically tracked advances in detecting synthetic GHRH analogs as they evolve to evade older tests ^[21]. This matters for the ordinary reader for one practical reason: the existence of this whole detection arms race confirms these are recognized performance-enhancing compounds in the anti-doping world, not harmless supplements. A 2026 critical review of peptide and peptide-analog doping in recreational and professional sport documents how widespread and organized this use has become outside clinical settings ^[22]. If you're a competitive athlete in any tested sport, treat all four of these compounds as banned substances, full stop, regardless of how a peptide clinic markets them.

How should someone actually choose between these, or decide if any make sense?

Start with the diagnosis, not the peptide name. Sermorelin and tesamorelin have documented clinical uses (historical, in sermorelin's case, and current for tesamorelin), tied to specific conditions: growth hormone deficiency workups and HIV-associated lipodystrophy, respectively. If you don't have a diagnosed deficiency or condition matching one of those, you're in off-label or unapproved territory no matter which peptide you pick. If a clinic is recommending CJC-1295 or ipamorelin, ask directly what bulk substance list, if any, their compounding pharmacy is sourcing from, and ask to see real bloodwork monitoring plans (IGF-1 at minimum, plus routine labs). A legitimate provider-reviewed process should include baseline labs, a clear rationale tied to your specific symptoms or diagnosis, and follow-up testing, more than a subscription box. Sermorelin Co works with a provider-reviewed process that connects patients to licensed prescribers and names the fulfilling pharmacy partner directly, rather than shipping product with no clinical oversight attached. That's a meaningfully different model from anonymous research-chemical vendors, and it's worth asking any provider you're considering whether they operate the same way. For a broader look at how sermorelin is typically delivered, sermorelin peptide injection vs oral and sermorelin peptide therapy near me are useful next reads, and if you're comparing sermorelin against oral secretagogues specifically, mk-677 vs sermorelin covers that specific comparison in depth.

Frequently asked questions

Is CJC-1295 the same as sermorelin?

No. Both are GHRH analogs that stimulate the pituitary the same general way, but CJC-1295 is chemically modified for a much longer half-life (days, in the DAC form), while sermorelin's half-life is minutes. CJC-1295 has no FDA approval; sermorelin was previously FDA-approved as Geref, since discontinued for business reasons, not safety.

Is ipamorelin a GHRH like sermorelin?

No. Ipamorelin is a ghrelin receptor agonist (a growth hormone secretagogue), working through the GHSR-1a receptor, a different mechanism than sermorelin, CJC-1295, or tesamorelin, all of which work through the GHRH receptor. Both pathways end up stimulating pituitary GH release, just through separate signaling routes.

Why was Geref (sermorelin) discontinued?

Geref was discontinued as a business decision by its manufacturer, not because of an FDA safety withdrawal. There's no documented safety finding that removed it from the market; production and marketing of the branded product simply stopped, and sermorelin is now generally available through compounding pharmacies instead.

Is tesamorelin better than sermorelin?

They're not really interchangeable, since tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy fat reduction, while sermorelin's approved history was in growth hormone deficiency diagnosis and treatment in children. "Better" depends entirely on which condition you're treating; neither is approved for general anti-aging or fitness use.

Which of these four peptides is FDA-approved right now?

Only tesamorelin currently holds active FDA approval, and only for reducing excess abdominal fat in HIV-associated lipodystrophy. Sermorelin held approval in the past as Geref, now discontinued. CJC-1295 and ipamorelin have never held FDA approval for any indication.

Can you combine sermorelin with CJC-1295 or ipamorelin?

Some prescribers and research protocols pair a GHRH analog with a ghrelin-mimetic like ipamorelin because they work through different receptors, and combined-mechanism GH secretagogue use is discussed in the literature. That's a pharmacologic rationale, not proof of specific outcomes; combining unapproved compounds adds regulatory and monitoring complexity beyond either used alone.

Is sermorelin legal to buy?

Sermorelin is generally available legally through compounding pharmacies with a prescription, under Section 503A of the FD&C Act (21 U.S.C. 353a). Buying it without a prescription from an unregulated seller, or buying CJC-1295/ipamorelin marketed as "research use only" for personal injection, sits in much murkier legal and safety territory.

How is sermorelin different from HGH injections directly?

Sermorelin signals the pituitary to make its own GH, so it depends on a functioning pituitary and produces a smaller, more feedback-regulated rise in GH and IGF-1. Direct HGH injection is the finished hormone, bypasses the pituitary, and produces a larger, more predictable increase, which is why HGH replacement is usually necessary when pituitary function is significantly impaired.

What is CJC-1295 used for if it's not FDA-approved?

CJC-1295 is used off-label and in research settings to stimulate longer-duration GH release than sermorelin, due to its extended half-life. It has no approved medical indication, and current safety and efficacy reviews describe its human evidence base as thinner than approved GHRH-based drugs like tesamorelin.

Does ipamorelin help with muscle growth or fat loss?

Ipamorelin raises GH and downstream IGF-1 through ghrelin receptor activation, and GH secretagogues broadly have been shown to raise IGF-1 levels in hypogonadal men in controlled research. But ipamorelin itself has no FDA approval and no large controlled trials establishing specific muscle or fat-loss outcomes in healthy adults.

Are these peptides tested for in competitive sports drug testing?

Yes. GHRH analogs and ghrelin mimetics are banned substances in tested sports, and anti-doping labs have developed multiple mass spectrometry and immunoaffinity-based methods specifically to detect them in urine, plasma, and blood, an active area of ongoing analytical chemistry research.

What monitoring should happen while using sermorelin or tesamorelin?

A legitimate prescriber-monitored protocol typically includes baseline and follow-up IGF-1 levels, along with routine clinical evaluation, since IGF-1 is the standard proxy marker for GH axis activity. Programs with no bloodwork built in aren't practicing real clinical monitoring, regardless of how the product is marketed.

Sources

1. BioDrugs, 1999 (PMID 18031173): Review of sermorelin's use in diagnosing and treating idiopathic growth hormone deficiency in children.
2. FDA, Drugs@FDA database: Authoritative source for confirming current FDA approval status of any drug, including tesamorelin's approved indication.
3. American Journal of Men's Health, 2017 (PMID 28830317): Growth hormone secretagogue treatment raised serum IGF-1 levels in hypogonadal men.
4. Clinical Interventions in Aging, 2006 (PMID 18046908): Discusses sermorelin's mechanism and clinical rationale for adult-onset GH insufficiency management.
5. Cornell Law School LII, 21 U.S.C. 353a: Statutory basis for pharmacy compounding under Section 503A of the FD&C Act.
6. eCFR, 21 CFR 216.23: Final 503A bulk drug substances list governing which substances compounding pharmacies may legally use.
7. eCFR, 21 CFR 216.24: 503B bulk drug substances list applying to outsourcing facilities compounding at scale.
8. FDA, bulk drug substances under section 503A: FDA guidance describing which bulk drug substances are permitted for 503A compounding.
9. FDA, bulk drug substances nominated for compounding use: FDA's current list of substances nominated and under review for compounding use.
10. Drug Testing and Analysis, 2016 (PMID 26456392): Documented falsified and contaminated biopharmaceutical injectables circulating in the European gray market.
11. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics describing gaps and challenges in the developing evidence base.
12. Sports Medicine (Auckland), 2026 (PMID 41966639): Safety and efficacy review of approved versus unapproved peptide therapies for musculoskeletal injury and performance.
13. Translational Andrology and Urology, 2020 (PMID 32257855): Review of growth hormone secretagogues, including combined GHRH/ghrelin-mimetic mechanisms, in hypogonadal male body composition management.
14. Frontiers in Endocrinology, 2026 (PMID 42395176): Describes the gap between clinical evidence and patient self-administration of GH-IGF1 axis performance-enhancing peptides.
15. Annals of Translational Medicine, 2021 (PMID 33842627): Explores sermorelin as a potentially effective drug in patients with recurrent glioma.
16. Frontiers in Surgery, 2026 (PMID 42465868): Case report of anterior cervical osteophyte-related dysphagia in a long-term growth hormone user.
17. Drug Testing and Analysis, 2023 (PMID 37806509): Describes a cationic exchange SPE and triple quadrupole UHPLC-MS/MS method for detecting GHRHs in urine.
18. Journal of Pharmaceutical and Biomedical Analysis, 2022 (PMID 35298973): Describes an antibody-free ultrafiltration assay detecting GHRH in urine at low picogram-per-milliliter concentrations.
19. Analytical and Bioanalytical Chemistry, 2016 (PMID 26879649): Describes immunoaffinity purification and LC-HRMS/MS method for identifying GHRHs in human plasma.
20. Journal of Chromatography A, 2020 (PMID 32971474): Compares magnetic bead surface chemistries for immunopurification of GHRHs prior to mass spectrometry.
21. Drug Testing and Analysis, 2021 (PMID 34665524): Reviews advances in detecting synthetic GHRH analogs as detection methods evolve.
22. Journal of Sports Medicine and Physical Fitness, 2026 (PMID 41880199): Critical review documenting the extent of peptide and peptide-analog doping use in recreational and professional sport.